Posted in Life Science/Pharmaceutical
Last month, I had a post discussing the health care industry’s need to “unlearn.” They are not, however, the only industry which might benefit from unlearning. I recently came across this article discussing how targeting “gut bugs” could revolutionize the development of future drugs.
I am not enough of an expert in the field to know for certain if the strategy will work, but I do know that innovative new strategies often come out of “left field’ and tend to be dismissed by more “established” experts in the early stages of their development.
At a minimum, if you are in the pharmaceutical industry, the idea deserves serious consideration. Who knows it might even help you “jump the curve.”
Interested in other posts on the topic of unlearning? Check out these articles:
Jack Uldrich is a writer, futurist, public speaker and host of jumpthecurve.net. He is the author of seven books, including Jump the Curve and The Next Big Thing is Really Small: How Nanotechnology Will Change the Future of Your Business. He is also a frequent speaker on future technology and future trends, nanotechnology, innovation, change management and executive leadership to a variety of businesses, industries and non-profit organizations and trade associations.